Get the Stockscreener App
3.49
11.15%
0.35
Adial Pharmaceuticals Inc stock is traded at $3.49, with a volume of 56,444.
It is up +11.15% in the last 24 hours and down -33.40% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
See More
Previous Close:
$3.14
Open:
$3.07
24h Volume:
56,444
Relative Volume:
1.33
Market Cap:
$10.24M
Revenue:
Net Income/Loss:
$-7.77M
P/E Ratio:
-0.3524
EPS:
-9.9046
Net Cash Flow:
$-6.52M
1W Performance:
-10.51%
1M Performance:
-33.40%
6M Performance:
+115.43%
1Y Performance:
-62.51%
1-Day Range:
$3.07
$3.66
1-Week Range:
$3.00
$4.04
52-Week Range:
$1.31
$9.90
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
3.49 | 10.24M | 0 | -7.77M | -6.52M | -9.9046 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-03-26 | Initiated | Alliance Global Partners | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
Adial Pharmaceuticals appoints David Rubenstein as chief scientist By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Appoints David Rubenstein as Chief Scientist - citybiz
Adial Pharmaceuticals appoints David Rubenstein as chief scientist By Investing.com - Investing.com India
Adial Pharmaceuticals names former Dermavant CSO as chief scientist - StreetInsider
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis - Yahoo! Finance Canada
The scientist who led development of an FDA-approved skin treatment will guide Adial's ulcerative colitis drug. - Stock Titan
Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing Decision - The Globe and Mail
Adial Pharmaceuticals adjourns votes pending Nasdaq listing approval, reconvenes Oct 15 - TradingView
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
A new hire's right to buy 155,446 Adial shares vests over four years. - Stock Titan
Director at Adial Pharma (NASDAQ: ADIL) gets 25,666 stock options - Stock Titan
Adial Pharmaceuticals Removes Penalty Provisions in PIPE and Note Exchange to Restore Nasdaq Compliance - TradingView
Why Did Adial Pharmaceuticals (ADIL) Stand Out? - Kalkine Media
Why Did Adial Pharmaceuticals (ADIL) Stand Out? - kalkinemedia.com
Adial Pharmaceuticals Inc Warrant (ADILW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Adial Pharmaceuticals to replace CEO and CFO after 2026 annual meeting - scanx.trade
Adial PharmaceuticalsProposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling StockholdersSEC Filing - TradingView
Adial Pharmaceuticals files prospectus for resale of 25.1 million shares - scanx.trade
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
A new Adial employee gets a 307,814-share option at $5.76 - Stock Titan
Adial (ADIL) Financial Update: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Session Move - vinanet.vn
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge - TipRanks
Adial Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Adial (ADIL) Watch: Ends Up by 5.42% at $6.22 in the Latest Reading; Price Context: $5.91 and $6.53 Define the Nearby Reference Levels in the Latest SessionSkew Index - vinanet.vn
Adial (ADIL) Financial Update: EPS Exceeds Its Estimate on the Day; Post-Report Move: Shares Move 9.22% Up at the CloseRevenue Breakdown Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Jumps 15% as Trading Volume AcceleratesFade Trade - vinanet.vn
Adial Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Adial Closes $32M Tranche of $64M Financing for Ulcerative Colitis Drug Development - Minichart
Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals Releases Q2 2026 Financial Results - news.alphastreet.com
Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Canada
Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com UK
Weekly Recap: Cash shortfall, warrant reliance and CEO succession, CFO exit - TradingView
Adial Reports $52 Million Second-Quarter Net Loss After Azora Acquisition - Quiver Quantitative
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - The Manila Times
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - GlobeNewswire
ADIL Q1 2026 Earnings: EPS Surprise Amid Revenue AbsenceDividend Growth Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsSector Leader Stocks - dars.gov.et
Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsWyckoff Spring - vinanet.vn
Adial Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Adial Pharmaceuticals (NASDAQ: ADIL) lifts cash to $28.7M but flags going‑concern risk - Stock Titan
Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Canada
Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com
Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com
Adial Pharmaceuticals Plans Major Leadership and Board Transition - TipRanks
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adial Pharmaceuticals Inc Stock (ADIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coastlands Capital LP | 10% Owner |
Jul 16 '26 |
Buy |
2.75 |
1,233 |
3,391 |
388,308 |
| Coastlands Capital LP | 10% Owner |
Jul 10 '26 |
Buy |
2.70 |
1,700 |
4,590 |
385,075 |
| Coastlands Capital LP | 10% Owner |
Jul 09 '26 |
Buy |
2.79 |
10,053 |
28,048 |
383,375 |
| Coastlands Capital LP | 10% Owner |
Jun 29 '26 |
Buy |
2.60 |
25,000 |
65,000 |
373,322 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):